4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

Rhea-AI Summary

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) will participate in the 2022 Bank of America Healthcare Conference on May 10, 2022, at 8:40 a.m. PT. The event will feature a fireside chat, accessible via a live audio webcast on the 4DMT website. This clinical-stage biotherapeutics company focuses on genetic medicines and has developed targeted vectors for five clinical products addressing diseases in ophthalmology, cardiology, and pulmonology, including Fabry disease and cystic fibrosis.

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the 2022 Bank of America Healthcare Conference on Tuesday, May 10^th. Details of the fireside chat are as follows:

Event: BofA Securities 2022 Healthcare Conference

Date & Time: Tuesday, May 10, 2022 at 8:40 a.m. PT

A live audio webcast of the presentation will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

About 4DMT

4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent targeted and evolved vectors for use in our products. The company is initially focused on five clinical-stage products in three therapeutic areas for both rare and large market diseases: ophthalmology, cardiology (including Fabry disease) and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The five 4DMT product candidates in clinical development are: 4D-310 for Fabry disease, 4D-150 for wet AMD, 4D-125 for XLRP, 4D-110 for choroideremia and 4D-710 for cystic fibrosis.

Contacts:

Media:

Ingrid Mezo
Canale Communications
ingrid.mezo@canalecomm.com

Investors:

Mike Zanoni
VP, Investor Relations
mzanoni@4dmt.com

FAQ

When is 4D Molecular Therapeutics participating in the Bank of America Healthcare Conference?

4D Molecular Therapeutics will participate on May 10, 2022, at 8:40 a.m. PT.

How can I access the live presentation of 4D Molecular Therapeutics at the conference?

The live audio webcast can be accessed through the 'Investors & Media' section of the 4D Molecular Therapeutics website.

What is the focus of 4D Molecular Therapeutics?

4D Molecular Therapeutics focuses on targeted genetic medicines, utilizing directed evolution for developing its biotherapeutic products.

What diseases does 4D Molecular Therapeutics target with its products?

4D Molecular Therapeutics targets diseases in ophthalmology, cardiology (including Fabry disease), and pulmonology.

What are the product candidates currently in development by 4D Molecular Therapeutics?

The product candidates include 4D-310 for Fabry disease, 4D-150 for wet AMD, 4D-125 for XLRP, 4D-110 for choroideremia, and 4D-710 for cystic fibrosis.